(Alliance News) - Shares in Nuformix PLC surged on Wednesday when it said results from its pre-clinical pilot study and the evaluation of its NXP004 fibrosis programme in human idiopathic pulmonary fibrosis have been "very encouraging".
Idiopathic pulmonary fibrosis is characterised by excessive deposition and remodelling of extracellular matrix which leads to lung scarring and loss of respiratory function.
The pharmaceutical development firm said NXP004 showed a reduction in the secretion of several key extracellular matrix, suggesting that the treatment compares favourably to the current standard of care.
Nuformix said it will now focus on delivering a full pre-clinical study data set in multiple human IPF tissue samples.
"Whilst this is only the pilot phase of this pre-clinical study, positive indications of anti-fibrotic activity are very encouraging. We would like to thank our research partner NFRG for prioritising completion of this study under challenging circumstances," said Chief Scientific Officer Joanne Holland.
The stock was trading 21% higher at 4.77 pence each on Wednesday afternoon in London.
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Nuformix (NFX)